Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 4;13(8):1200.
doi: 10.3390/pharmaceutics13081200.

Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine

Nolwenn Tessier  1   2 , Fatma Moawad  3   4 , Nada Amri  1   2 , Davide Brambilla  3 , Catherine Martel  1   2
Affiliations
Review

Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine

Nolwenn Tessier et al. Pharmaceutics. .

Abstract

While oral agents have been the gold standard for cardiovascular disease therapy, the new generation of treatments is switching to other administration options that offer reduced dosing frequency and more efficacy. The lymphatic network is a unidirectional and low-pressure vascular system that is responsible for the absorption of interstitial fluids, molecules, and cells from the peripheral tissue, including the skin and the intestines. Targeting the lymphatic route for drug delivery employing traditional or new technologies and drug formulations is exponentially gaining attention in the quest to avoid the hepatic first-pass effect. The present review will give an overview of the current knowledge on the involvement of the lymphatic vessels in drug delivery in the context of cardiovascular disease.

Keywords: cardiovascular diseases; drug delivery route; lymphatics; nanotechnology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Kaptoge S., Pennells L., De Bacquer D., Cooney M.T., Kavousi M., Stevens G., Riley L.M., Savin S., Khan T., Altay S., et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Glob. Health. 2019;7:e1332–e1345. doi: 10.1016/S2214-109X(19)30318-3. - DOI - PMC - PubMed
    1. Virani S.S., Alonso A., Aparicio H.J., Benjamin E.J., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Cheng S., Delling F.N. Heart disease and stroke statistics—2021 update: A report from the American Heart Association. Circulation. 2021;143:e254–e743. doi: 10.1161/CIR.0000000000000950. - DOI - PubMed
    1. Tiwari G., Tiwari R., Sriwastawa B., Bhati L., Pandey S., Pandey P., Bannerjee S.K. Drug delivery systems: An updated review. Int. J. Pharm. Investig. 2012;2:2. doi: 10.4103/2230-973X.96920. - DOI - PMC - PubMed
    1. Ryan G.M., Kaminskas L.M., Porter C.J. Nano-chemotherapeutics: Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. J. Control. Release. 2014;193:241–256. doi: 10.1016/j.jconrel.2014.04.051. - DOI - PubMed
    1. Maisel K., Sasso M.S., Potin L., Swartz M.A. Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges. Adv. Drug Deliv. Rev. 2017;114:43–59. doi: 10.1016/j.addr.2017.07.005. - DOI - PMC - PubMed

LinkOut - more resources